Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: A randomised controlled trial

Current Medical Research and Opinion

Volumn 29, Issue 10, 2013, Pages 1357-1369

  Pertseva, Tetyana ^a   Dissanayake, Sanjeeva ^b   Kaiser, Kirsten ^c  

^a Dnipropetrovsk State Medical Academy   (Ukraine)

^b Mundipharma Research Limited   (United Kingdom)

^c SkyePharma   (Switzerland)

Author keywords

Asthma; Combination therapy; Fluticasone propionate; Flutiform; Formoterol fumarate; ICS LABA

Indexed keywords

FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; PREDNISONE; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHILD; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GASTRITIS; HEADACHE; HUMAN; INFLUENZA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MONOTHERAPY; PEAK EXPIRATORY FLOW; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SCHOOL CHILD; SLEEP DISORDER; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAL SIGN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84884484526     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.825592     Document Type: Article

References (14)

1. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma, a report for the Global Initiative for Asthma. 2004. Available at: http://www.ginasthma. org [Last accessed June 2012]
2. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011. Available at: http://www.ginasthma.org [Last accessed June 2012]
3. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007;29:587-95 (Pubitemid 46372109)
4. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245-51 (Pubitemid 38210545)
5. Ketchell RI, Jensen MW, Lumley P, et al. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5-monophosphate in mild asthma. J Allergy Clin Immunol 2002;110:603-6 (Pubitemid 35178796)
6. Luijk B, Kempsford RD, Wright AM, et al. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004;23:559-64 (Pubitemid 38455997)
7. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13:988-92 (Pubitemid 29288919)
8. Bodzenta-Lukaszyk A, Dymek A, McAulay K, et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulmonary Medicine 2011;11:28
9. National Asthma Education and Prevention Program, National Institute of Health, National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. 1997, Publication No. 97-4051
10. Bodzenta-Lukaszyk A, Pulka G, Dymek A, et al. Efficacy and safety of fluti-casone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011;105:674-82
11. Nathan RA, D'Urzo A, Blazhko V, et al. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulmonary Medicine 2012;12:67
12. Corren J, Mansfield LE, Pertseva T, et al. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med 2013;107:180-95
13. Drugs@FDA. Symbicort Summary Basis for Approval. Updated 25 June 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 021929s021lbl.pdf [Last accessed 5 November 2012]
14. Drugs@FDA. Advair Diskus 250/50 Summary Basis for Approval. Updated 25 June 2010. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2010/021077s042lbl.pdf [Last accessed 5 November 2012]